Navigation Links
Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Date:8/26/2009

LACHEN, Switzerland and HOBOKEN, N.J., Aug. 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide. Globally, 75% of the hemophilia cases go undiagnosed or untreated.

Octapharma AG, the third largest plasma products manufacturer in the world, recently brought together many of the most respected blood coagulation disorder researchers for two symposia on this important issue during the International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress in Boston. Octapharma was one of only five Platinum Sponsors at the ISTH Congress, which attracted approximately 7,500 representatives of the medical and research community as well as many patients.

Clinical experts noted during the symposia that up to 40 percent of previously untreated patients (PUPs) with hemophilia A develop the most serious clinical complication of FVIII replacement therapy - inhibitory antibodies - which can result in uncontrolled hemorrhage, increased hospitalizations and joint damage, resulting in increased morbidity and mortality.

"We brought the international community together to confront this issue because our worldwide commitment to hemophilia A patients dates back to Octapharma's formation 25 years ago," said Octapharma AG Vice Chairman '/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
2. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 Point-of-Care Partners, a ... consulting firm, has launched the ePA State Navigator ... IT vendors, payers and pharmacies to quickly assess ... authorization (ePA) of prescription medications. Today, ... are completed through time-consuming, manual processes amongst prescribers, ...
(Date:3/31/2015)... ROCHELLE, N.Y. , March 31, 2015 /PRNewswire-USNewswire/ ... it will be featured in the American Medical ... by ITN Productions. AMGA,s "High Performing ... on the challenges facing the nation,s healthcare system ... Medical Letter is profiled along with other leading ...
(Date:3/31/2015)... March 31, 2015 RnRMarketResearch.com ... market research report of 68 pages with latest ... intelligence library. The report "Pemphigus - Pipeline Review, ... therapeutic development for Pemphigus , complete with ... drug target, mechanism of action (MoA), route of ...
Breaking Medicine Technology:Point-of-Care Partners Launches the ePA State Navigator 2AMGA's High Performing Health News Program Features The Medical Letter 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... , , ... Inc.,("Chindex") (Nasdaq: CHDX ), a leading independent American provider of ... that the Company will attend the 21st Annual Piper Jaffray,"Unplugged" Health ... the,New York Palace Hotel. , Management is ...
... SAN DIEGO, Nov. 24 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 21st Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, ... conference is being held at The New York Palace Hotel. ... Anadys, will provide an overview of Anadys and its clinical ...
Cached Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2
(Date:4/1/2015)... Mount, North Carolina (PRWEB) April 01, 2015 ... care and assisted living placement counseling, recently opened a new ... location. Amada franchise partners Tracy and Lee Bissett decided to ... the rights to the area after over 20 years of ... held on Thursday, April 2nd. , When asked ...
(Date:4/1/2015)... Francisco, CA (PRWEB) April 01, 2015 ... , and the international children’s medical charity, Operation ... their new global partnership. , Campaign Details: RxOrganics ... Rxmedical line to Operation Smile throughout 2015. ... based on such sales so that every order placed ...
(Date:4/1/2015)... CT (PRWEB) April 01, 2015 Results ... Energy Challenge , which featured 11 new homes from ... construct residences that best utilized innovative building techniques and ... or net-zero. Steven Winter Associates, Inc. (SWA) provided sustainability ... into this year’s challenge, including the first- and third-place ...
(Date:4/1/2015)... Brook, IL (PRWEB) April 01, 2015 ... benefited greatly from climate change in recent years, increasing ... develop an allergic reaction if exposed to poison plants ... outdoor enthusiasts and families prepare for summer adventures in ... an uncomfortable poison plant reaction is greater than ever. ...
(Date:3/31/2015)... Bon Secours New York Health System welcomed ... Care Center family last week. The Sisters formerly resided ... which is scheduled to close later this year. , ... Sisters of Charity of New York, the decision by ... their Sisters at Schervier Nursing Care Center followed an ...
Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2
... 2010 The John Theurer Cancer Center at Hackensack ... researchers will present 16 abstracts on treatment and diagnostic ... Annual Meeting of American Society of Clinical Oncology (ASCO) ... "At the John Theurer Cancer Center, we,re dedicated to ...
... Americans now have ... same treatment in the USA, Medical Tourism is the answer. , ... Carlsbad, CA (PRWEB) June 2, 2010 – Website promotes the healthcare ... the USA. , , ,Global Medical Connect is a one stop medical tourism shop to take ...
... explain deadly mistakes, study suggests , THURSDAY, June 3 ... peak in July, possibly because of the inexperience of ... begin their medical residencies in July, and those first ... teaching hospitals, suggest researchers at the University of California, ...
... ,early and often, some suggest, but others say it,s not ... Explaining where babies come from prompts anxiety in many a ... or sperm donors into the story can make an already ... facing a growing number of parents. , As assisted reproduction ...
... , ... Real Salt Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part ... ... Lake and the United Nations Foundation ’s Nothing But Nets campaign are teaming up ...
... ... an ongoing market research study that provides detailed analyses on health plans’ coverage ... ... Companies (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides ...
Cached Medicine News:Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Global Medical Connect Launches New Website for the Growing Medical Tourism Industry 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
Medicine Products: